Search results

 

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
You searched for:
Results: 66
1

Respiratory diseases

Respiratory diseases   Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the...
2

Neonatology

Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...
3

Intensive care

Anaesthesiology, Algesiology and Intensive Medicine represent key areas of the company’s operation. A wide range of products was in-licenced for these specific areas of medicine.
4

Transplantation

Solid organ transplantation   A transplantation becomes necessary if an organ is no longer able to fulfil all of its functions. Today, this treatment method is a well-established, successful procedure, such that most patients can once again lead an almost normal life after the organ...
5

Jiné

-
6

Rare disease

-
7

Site Map

-
8

About us

Chiesi CZ s.r.o., is an affiliate of Chiesi Farmaceutici S.p.A. based in Parma, Italy - a multinational pharmaceutical company with more than 80 years of experience. Chiesi group focuses mainly on the research, development, production and marketing of innovative medicines...
9

Press release

-
10

Production plants

Chiesi Group has three production plants:   Parma, Italy. Blois-La Chaussée-Saint-Victor, France. Santana de Parnaíba, Brazil.   The plants produce in the whole more than 110 million units per year.   Italy     The production plant in Parma covers a total area of more than...
11

Cookies

Cookie Policy   This policy provides information regarding the use of cookies and other similar technologies on the website www.chiesi.cz (hereinafter referred to as the "Website"). This notice is provided to the user in compliance with European legislation on the processing of personal data...
12

Products

-
13

Search result

-
14

Therapeutic areas

-
15

Contacts

Chiesi CZ s.r.o.Smrčkova 2485/4 (DOCK IN TWO building)180 00 Praha 8, Česká Republika   Tel.: +420 261 221 745Fax: +420 261 221 767E-mail: chiesi-cz@chiesi.com   To report an adverse event and/or product defect E-mail: safety.cz@chiesi.comTel.: +420 261...
16

Management

-
17

GDPR

-
18

Anti-bribery Policy, Code of Ethics and Conduct

Guaranteeing the highest ethical standards at Chiesi is a priority which characterises every aspect of our day-to-day work. Our ethical principles are put into practice by affirming our values and protecting all areas involved in our activities. The society, the environment, and generally all those...
19

Transparency

Transparency   Within the European Federation of Pharmaceutical Industries and Associations (EFPIA), Chiesi is part of the "Transparent Cooperation" project of the Association of the Innovative Pharmaceutical Industry, which reflects the current global demands for ethics of cooperation...
20

Pharmacovigilance

Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal products...
21

Credits

  This project was edited and produced by Dynamic Mind.
22

VPOIS

-
23

Chiesi is B corp

      Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It’s an achievement to be proud of, and yet it feels natural: caring for others is at the root of health science and it has...
24

History

-
25

Disclaimer

-
26

Annual report

-
27

SpeakUp&BeHeard

-
28

Privacy-SpeakUp&BeHeard

PRIVACY NOTICE   This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing the reporting individuals on how we process...
29

Facebook Community Guidelines

Chiesi Farmaceutici S.p.A. (Chiesi Group) Facebook page is designed for sharing information, news and events relating to the world of health or to the Chiesi Group. We are delighted that you are in touch with us on Facebook.   The following information contains the Terms of Use (hereafter...
30

Working for Chiesi

Build your career with us!     Our culture belongs to the brave and the curious. At Chiesi we focus on finding innovative solutions and embracing new challenges. Every choice we make is driven by the will to generate a positive impact both on our community and our...
31

News

-
32

Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group

-
33

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

CAMBRIDGE, Mass. and Parma, Italy   Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare...
34

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences   New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a B Corp certified business Patients’ experiences and...
35

Chiesi Group receives European Marketing Authorisation for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy fo

Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) / long-acting muscarinic...
36

Chiesi Group calls for #ActionOverWords in the fight against climate change

Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.   Parma (Italy), 10 May, 2021 – Chiesi Group, the...
37

New organisational order for the Chiesi Foundation

Maria Paola Chiesi, former Coordinator of the Foundation since 2010, succeeds Dr Paolo Chiesi. She is supported by Massimo Salvadori, Coordinator of the Chiesi Foundation since February.   Parma, May 3 2021 – On May 1 Maria Paola Chiesi was appointed President of the Chiesi...
38

Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma

Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients.1,2 This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe chronic obstructive pulmonary...
39

Chiesi accelerates path toward full sustainability despite Covid-19 pandemic

Ensuring continuing medical treatment for patients has been top priority during Covid-19 pandemic. Focus on Diversity & Inclusion in the workplace: 53% of all employees are women – ratio of female workers even higher in R&D (64%). All the company’s 2020 activities, data and...
40

Chiesi tracks actions taken for a healthier, more sustainable future

Chiesi tracks actions taken for a healthier, more sustainable future   Chiesi’s Annual and Sustainability Report 2021 is released today; Progress towards business, environmental and social targets is strong; Company is joining forces with all stakeholders to advance sustainable...
41

Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025

Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025   The Group has increased its B-Impact score by 16.3 points, with 103.8 out of 200 compared to its first certification in 2019; The recertification process by B Lab identifies further focus for action...
42

Chiesi appoints Giuseppe Accogli as new Group CEO

Chiesi appoints Giuseppe Accogli as new Group CEO   Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the Med-tech sector of reputed and complex companies such as Tyco Healthcare (Covidien), Baxter and Medtronic “As CEO, I strive to...
43

Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases

  Chiesi Group and Affibody will collaborate closely to develop novel Affibody® molecules as innovative treatments for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs. Affibody will receive...
44

What does it mean to be a B Corp? Chiesi's choice for a sustainable future

  Since 2017, March has been ‘B Corp Month’, dedicated to celebrating and raising awareness of a young, but already established global movement (the B Corp movement), born out of a revolutionary idea: using business as a force for good.     For centuries, our society...
45

Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair

Alessandro Chiesi has held the post of Chief Commercial Officer since 2020, and succeeds Alberto Chiesi, who, together with his brother Paolo, led the Group to global expansion over the past five decades.   Parma (Italy), July 7th, 2023 – Chiesi announces the appointment of...
46

CHIESI’S SUSTAINABILITY REPORT 2022: A YEAR OF TANGIBLE ACHIEVEMENTS FOR PATIENTS, COMMUNITIES, AND THE PLANET

Chiesi’s Sustainability Report 2022 is released today; The company has committed to reaching Net Zero GHG emissions by 2035; 130,000 units of Chiesi medicines, valued at €4.5 million, were donated to patients in conflict territories; The company closed the gender pay gap at Group...
47

Chiesi Group mid-year financial results demonstrate strong growth for 2023

Chiesi Group announces mid-year turnover of €1,497 million; Substantial growth of each of Chiesi’s business areas; Europe remains the biggest market, followed by the US and China; Forecasted revenues of about €3 billion for 2023, with an additional solid growth expected in...
48

Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)

Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto.   Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and...
49

Lamzede®

Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.   For more information about therapy you can find on the corporate webs Chiesi Global Rare Diseases.
50

Combair®

This fixed combination consists of an antiinflammatory inhalative corticosteroid and a long-acting bronchodilatory beta-2-sympathomimetic drug. Due to the synergism of both agents and its fast onset of action, it is indicated in the treatment of asthma bronchiale. Based on the Modulite®...
51

Peyona®

Peyona (caffeine citrate) is an orphan drug only for hospital use, registered by centralized procedure and indicated for the treatment of primary apnoea of premature newborns. This pathology is characterised by the incomplete development of the brain centres which control the respiration. The...
52

Otobacid N

This combination contains dexamethasone, an anti-inflammatory glucocorticoid, dibucaine (cinchocaine), a local anaesthetic and long-acting chinoline derivative, and butanediole, a polyvalent alcohol with antiseptic properties. It is used in the therapy of inflammatory diseases of the ear...
53

Fentanyl Torrex

Fentanyl, a powerful narcotic analgesic, is used as an analgetic component for general anaesthesia. It is approximately 100 times more potent than morphine and a very fast acting substance.
54

Atimos®

Formoterol is an inhalative long-acting beta-2-agonist which acts as a bronchodilator. It is indicated in patients with obstructive pulmonary disease.
55

Sufentanil Torrex

Sufentanil is a synthetic opioid analgesic drug which is seven to ten times more potent than Fentanyl. It is used either as analgesic component or as an anaesthetic agent for the induction and maintenance of balanced anaesthesia.
56

Envarsus®

Envarsus® is a once daily prolonged-release tablet containing tacrolimus monohydrate. The product is indicated for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for treatment of allograft rejection resistant to treatment with other immunosuppressive...
57

Bramitob®

Tobramycin is an aminoglycoside antibiotic which is produced by Streptomyces tenebrarius and it is administered via inhalative route. The therapeutic indication is the management of chronic pulmonary infections caused by pseudomonas aeruginosa in patients with cystic fibrosis.
58

Curosurf®

Our product is a natural surfactant for substituting a lack of endogenous surfactant and is administered via intratracheal instillation. It adheres to the alveoli and reduces the surface tension, thereby preventing atelectasis (ventilation deficiency in the lung). The insufficiency of surfactant...
59

Quinsair®

-
60

Trimbow®

-
61

Procysbi®

For more information about therapy you can find on the corporate webs Chiesi Global Rare Diseases.
62

Kengrexal®

-
63

Combair NEXThaler®

-
64

Trimbow NEXThaler®

-
65

Raxone®

For more information about therapy you can find on the corporate webs Chiesi Global Rare Diseases.
66

Ferriprox®

For more information about therapy you can find on the corporate webs Chiesi Global Rare Diseases.